+Compare
ORGO
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
344.04M

ORGO Organogenesis Holdings Forecast, Technical & Fundamental Analysis

a financial conglomerate

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for ORGO with price predictions
07:00 PM EST Nov 30, 2023

ORGO in upward trend: 10-day moving average moved above 50-day moving average on November 24, 2023

The 10-day moving average for ORGO crossed bullishly above the 50-day moving average on November 24, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ORGO's RSI Oscillator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 10, 2023. You may want to consider a long position or call options on ORGO as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ORGO just turned positive on November 13, 2023. Looking at past instances where ORGO's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

ORGO moved above its 50-day moving average on November 14, 2023 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ORGO advanced for three days, in of 254 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORGO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ORGO broke above its upper Bollinger Band on November 14, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ORGO entered a downward trend on November 16, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ORGO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.243) is normal, around the industry mean (47.989). P/E Ratio (26.178) is within average values for comparable stocks, (60.542). ORGO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.883). ORGO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.027). P/S Ratio (0.774) is also within normal values, averaging (65.502).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 2.76B. The market cap for tickers in the group ranges from 246 to 82.08B. ZTS holds the highest valuation in this group at 82.08B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 3%. For the same Industry, the average monthly price growth was 39%, and the average quarterly price growth was -6%. RDHL experienced the highest price growth at 426%, while CNTRF experienced the biggest fall at -57%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 204%. For the same stocks of the Industry, the average monthly volume growth was 17% and the average quarterly volume growth was 37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 68
Price Growth Rating: 61
SMR Rating: 84
Profit Risk Rating: 91
Seasonality Score: 24 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

ORGO is expected to report earnings to fall 75.00% to 0 cents per share on March 12

Organogenesis Holdings ORGO Stock Earnings Reports
Q4'23
Est.
$0.00
Q3'23
Beat
by $0.01
Q2'23
Est.
$0.04
Q1'23
Beat
by $0.02
Q4'22
Est.
$0.06
The last earnings report on November 09 showed earnings per share of 1 cents, beating the estimate of 0 cents. With 863.52K shares outstanding, the current market capitalization sits at 344.04M.
A.I. Advisor
published General Information

General Information

a financial conglomerate

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Financial Conglomerates
Address
85 Dan Road
Phone
+1 781 575-0775
Employees
1030
Web
https://www.organogenesis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PSGKX17.310.45
+2.67%
BlackRock Advantage Small Cap Gr K
CCMSX12.570.31
+2.53%
Cardinal Small Cap Value Institutional
NINCX17.680.40
+2.31%
Neuberger Berman Intrinsic Value C
RRGAX6.600.14
+2.17%
DWS RREEF Global Real Estate Secc A
MITJX34.880.15
+0.43%
MFS Massachusetts Investors Tr R6

ORGO and

Correlation & Price change

A.I.dvisor tells us that ORGO and DVAX have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ORGO and DVAX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORGO
1D Price
Change %
ORGO100%
+7.06%
DVAX - ORGO
33%
Poorly correlated
+0.66%
SIGA - ORGO
32%
Poorly correlated
+3.31%
ELAN - ORGO
32%
Poorly correlated
+5.26%
ACET - ORGO
29%
Poorly correlated
+4.24%
SBFM - ORGO
27%
Poorly correlated
+0.35%
More

Groups containing ORGO

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORGO
1D Price
Change %
ORGO100%
+7.06%
regenerative medicine
(undefined stocks)
65%
Loosely correlated
+21.42%
rental
(undefined stocks)
34%
Loosely correlated
+1.99%
banks
(undefined stocks)
31%
Poorly correlated
+3.47%
lease
(undefined stocks)
31%
Poorly correlated
+1.39%
financial conglomerate
(undefined stocks)
29%
Poorly correlated
+1.34%
More